Results 21 to 30 of about 6,757 (189)

An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis

OncoImmunology, 2022
Type 1 conventional dendritic cells (cDC1) efficiently cross-present antigens that prime cytotoxic CD8+ T cells. cDC1 therefore constitute conceivable targets in cancer vaccine development.
Mohammad Arabpour, Sanchari Paul, Hanna Grauers Wiktorin, Mustafa Kaya, Roberta Kiffin, Nils Lycke, Kristoffer Hellstrand, Anna Martner   +7 more
doaj   +1 more source

cDC1 Subtype-Specific In Vivo Targeting of Liposomes. [PDF]

Adv Sci (Weinh)
ABSTRACT Targeted modulation of immune cells holds great promise for improving therapeutic efficacy and minimizing systemic side effects; however, current strategies with nanocarriers often rely on untargeted or labor‐intensive approaches. To bridge this gap, combining clinically approved nanocarrier systems like liposomes with highly
Schaaf M, Fichter M, Jian L, Schön F, Jung C, Schneider P, Speth K, Mateos-Maroto A, Mailänder V, Koynov K, Morsbach S, Landfester K.   +11 more
europepmc   +4 more sources

Supplementary Figure from cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1

, 2023
Supplementary Figure from cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host ...
Kenneth M. Murphy, Theresa L. Murphy, Robert D. Schreiber, Tian-Tian Liu, Jing Chen, Sunkyung Kim, Xiao Huang, Renee Wu, Feiya Ou, Ray A. Ohara, Stephen T. Ferris   +10 more
openaire   +1 more source

Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?

Frontiers in Immunology, 2019
Dendritic cells (DCs) are endowed with a unique potency to prime T cells, as well as to orchestrate their expansion, functional polarization and effector activity in non-lymphoid tissues or in their draining lymph nodes.
Jean-Charles Cancel, Karine Crozat, Marc Dalod, Raphaël Mattiuz   +3 more
doaj   +1 more source

Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy

Frontiers in Immunology, 2023
BackgroundThe use of circulating cDC1 to generate anti-cancer vaccines is among the most promising approaches to overcome the limited immunogenicity and clinical efficacy of monocyte-derived DC.
Beatris Mastelic-Gavillet, Beatris Mastelic-Gavillet, Apostolos Sarivalasis, Leyder Elena Lozano, Leyder Elena Lozano, Sebastien Lofek, Sebastien Lofek, Tania Wyss, Tania Wyss, Tania Wyss, Ignacio Melero, Ignacio Melero, Ignacio Melero, Ignacio Melero, I. Jolanda M. de Vries, Alexandre Harari, Alexandre Harari, Pedro Romero, Pedro Romero, Lana Elias Kandalaft, Lana Elias Kandalaft, Selena Viganó, Selena Viganó   +22 more
doaj   +1 more source

Interaction of Type 1 Porcine Reproductive and Respiratory Syndrome Virus With In Vitro Derived Conventional Dendritic Cells

Frontiers in Immunology, 2021
The present study delineates the interaction of a typical PRRSV1.1 isolate 3267 (moderate virulence) with in vitro derived pig conventional dendritic cells, cDC1, cDC2, and a CD14+ population (designated as CD14+ DCs).
Yanli Li, Enric Mateu, Enric Mateu
doaj   +1 more source

Human cDC1s display constitutive activation of the UPR sensor IRE1

European Journal of Immunology, 2022
AbstractThe intracellular mechanisms safeguarding DC function are of biomedical interest in several immune‐related diseases. Type 1 conventional DCs (cDC1s) are prominent targets of immunotherapy typified by constitutive activation of the unfolded protein response (UPR) sensor IRE1.
Paulina García‐González, Dominique Fernández, Diane Gutiérrez, Mauro Parra‐Cordero, Fabiola Osorio   +4 more
openaire   +3 more sources

cDC1s: New Orchestrators of Tissue Innate Immunity

Trends in Immunology, 2019
Type-I conventional dendritic cells (cDC1s) are key in inducing adaptive immunity. Using single-cell sequencing, Ginhoux and colleagues (Immunity 2019;50:1069-1083.e8) find that a subset of activated cDC1s in bacteria-infected skin is critical for neutrophil recruitment via the production of VEGF-α.
del Fresno, Carlos, Sancho, David
openaire   +3 more sources

STAT3 Inhibits CD103+ cDC1 Vaccine Efficacy in Murine Breast Cancer [PDF]

Cancers, 2020
Conventional dendritic cells (cDCs) are a critical immune population, composed of multiple subsets, and responsible for controlling adaptive immunity and tolerance. Although migratory type 1 cDCs (CD103+ cDC1s in mice) are necessary to mount CD8+ T cell-mediated anti-tumor immunity, whether and how tumors modulate CD103+ cDC1 function remain ...
Taylor T. Chrisikos, Yifan Zhou, Haiyan S. Li, Rachel L. Babcock, Xianxiu Wan, Bhakti Patel, Kathryn Newton, James J. Mancuso, Stephanie S. Watowich   +8 more
openaire   +2 more sources

Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer [PDF]

Frontiers in Immunology, 2021
Immunotherapeutic approaches have revolutionized the treatment of several diseases such as cancer. The main goal of immunotherapy for cancer is to modulate the anti-tumor immune responses by favoring the recognition and destruction of tumor cells. Recently, a better understanding of the suppressive effect of the tumor microenvironment (TME) on immune ...
Bödder, J., Zahan, T., van Slooten, R., Schreibelt, G., de Vries, I.J.M., de Vries, I.J.M., Flórez-Grau, G.   +6 more
openaire   +4 more sources